Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma
Abstract Background Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance of well-known biological markers for cardiovascular disease (CVD) as NTproBNP and Troponins may be helpful, there are no established m...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-02-01
|
Series: | Cardio-Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40959-021-00092-0 |
id |
doaj-bdac96d3082349749fc137196b3d3689 |
---|---|
record_format |
Article |
spelling |
doaj-bdac96d3082349749fc137196b3d36892021-02-07T12:19:45ZengBMCCardio-Oncology2057-38042021-02-017111310.1186/s40959-021-00092-0Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphomaCharlott Mörth0Amal Abu Sabaa1Eva Freyhult2Christina Christersson3Jamileh Hashemi4Nashmil Hashemi5Masood Kamali-Moghaddam6Daniel Molin7Martin Höglund8Anna Eriksson9Gunilla Enblad10Department of Immunology, Genetics & Pathology, Uppsala UniversityDepartment of Immunology, Genetics & Pathology, Uppsala UniversityDepartment of Medical Sciences, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala UniversityDepartment of Medical Sciences, Uppsala UniversityDepartment of Immunology, Genetics & Pathology, Uppsala UniversityDepartment of Cardiology, Danderyd Hospital, Karolinska InstituteDepartment of Immunology, Genetics & Pathology, Science for Life Laboratory, Uppsala UniversityDepartment of Immunology, Genetics & Pathology, Uppsala UniversityDepartment of Medical Sciences, Uppsala UniversityDepartment of Medical Sciences, Uppsala UniversityDepartment of Immunology, Genetics & Pathology, Uppsala UniversityAbstract Background Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance of well-known biological markers for cardiovascular disease (CVD) as NTproBNP and Troponins may be helpful, there are no established markers to monitor for evolving CVD during treatment. New possibilities have arisen with the emergence of newer techniques allowing for analysis of plasma proteins that can be associated with cardiovascular disease. Proximity Extension Assay is one of them. Objectives We aimed to illustrate the incidence of CVD in DLBCL patients treated with DXR and to establish whether there are plasma proteins associated with pre-existing or emerging CVD. Methods In 95 patients, 182 different proteins from OLINK panels, NTproBNP, Troponin I and CRP were assessed prior to, during and after treatment. For comparison, samples from controls were analyzed. Results In the DLBCL cohort, 33.3% had pre-treatment CVD compared to 5.0% in the controls and 23.2% developed new CVD. Of the 32.6% who died during follow up, CVD was the cause in 4 patients. Spondin-1 (SPON-1) correlated to pre-treatment CVD (1.22 fold change, 95% CI 1.10–1.35, p = 0.00025, q = 0.045). Interleukin-1 receptor type 1 (IL-1RT1) was associated to emerging CVD (1.24 fold change, 95% CI 1.10–1.39, p = 0.00044, q = 0.082). Conclusion We observed a higher prevalence of CVD in DLBCL patients compared to controls prior to DXR therapy. Two proteins, SPON-1 and IL-1RT1, were related to pre-existing and emerging CVD in DXR treated patients. If confirmed in larger cohorts, IL-1RT1 may emerge as a reliable biomarker for unfolding CVD in DLBCL.https://doi.org/10.1186/s40959-021-00092-0ProteomicsLymphomaCardiac toxicityDoxorubicin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Charlott Mörth Amal Abu Sabaa Eva Freyhult Christina Christersson Jamileh Hashemi Nashmil Hashemi Masood Kamali-Moghaddam Daniel Molin Martin Höglund Anna Eriksson Gunilla Enblad |
spellingShingle |
Charlott Mörth Amal Abu Sabaa Eva Freyhult Christina Christersson Jamileh Hashemi Nashmil Hashemi Masood Kamali-Moghaddam Daniel Molin Martin Höglund Anna Eriksson Gunilla Enblad Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma Cardio-Oncology Proteomics Lymphoma Cardiac toxicity Doxorubicin |
author_facet |
Charlott Mörth Amal Abu Sabaa Eva Freyhult Christina Christersson Jamileh Hashemi Nashmil Hashemi Masood Kamali-Moghaddam Daniel Molin Martin Höglund Anna Eriksson Gunilla Enblad |
author_sort |
Charlott Mörth |
title |
Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma |
title_short |
Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma |
title_full |
Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma |
title_fullStr |
Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma |
title_full_unstemmed |
Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma |
title_sort |
plasma proteome profiling of cardiotoxicity in patients with diffuse large b-cell lymphoma |
publisher |
BMC |
series |
Cardio-Oncology |
issn |
2057-3804 |
publishDate |
2021-02-01 |
description |
Abstract Background Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance of well-known biological markers for cardiovascular disease (CVD) as NTproBNP and Troponins may be helpful, there are no established markers to monitor for evolving CVD during treatment. New possibilities have arisen with the emergence of newer techniques allowing for analysis of plasma proteins that can be associated with cardiovascular disease. Proximity Extension Assay is one of them. Objectives We aimed to illustrate the incidence of CVD in DLBCL patients treated with DXR and to establish whether there are plasma proteins associated with pre-existing or emerging CVD. Methods In 95 patients, 182 different proteins from OLINK panels, NTproBNP, Troponin I and CRP were assessed prior to, during and after treatment. For comparison, samples from controls were analyzed. Results In the DLBCL cohort, 33.3% had pre-treatment CVD compared to 5.0% in the controls and 23.2% developed new CVD. Of the 32.6% who died during follow up, CVD was the cause in 4 patients. Spondin-1 (SPON-1) correlated to pre-treatment CVD (1.22 fold change, 95% CI 1.10–1.35, p = 0.00025, q = 0.045). Interleukin-1 receptor type 1 (IL-1RT1) was associated to emerging CVD (1.24 fold change, 95% CI 1.10–1.39, p = 0.00044, q = 0.082). Conclusion We observed a higher prevalence of CVD in DLBCL patients compared to controls prior to DXR therapy. Two proteins, SPON-1 and IL-1RT1, were related to pre-existing and emerging CVD in DXR treated patients. If confirmed in larger cohorts, IL-1RT1 may emerge as a reliable biomarker for unfolding CVD in DLBCL. |
topic |
Proteomics Lymphoma Cardiac toxicity Doxorubicin |
url |
https://doi.org/10.1186/s40959-021-00092-0 |
work_keys_str_mv |
AT charlottmorth plasmaproteomeprofilingofcardiotoxicityinpatientswithdiffuselargebcelllymphoma AT amalabusabaa plasmaproteomeprofilingofcardiotoxicityinpatientswithdiffuselargebcelllymphoma AT evafreyhult plasmaproteomeprofilingofcardiotoxicityinpatientswithdiffuselargebcelllymphoma AT christinachristersson plasmaproteomeprofilingofcardiotoxicityinpatientswithdiffuselargebcelllymphoma AT jamilehhashemi plasmaproteomeprofilingofcardiotoxicityinpatientswithdiffuselargebcelllymphoma AT nashmilhashemi plasmaproteomeprofilingofcardiotoxicityinpatientswithdiffuselargebcelllymphoma AT masoodkamalimoghaddam plasmaproteomeprofilingofcardiotoxicityinpatientswithdiffuselargebcelllymphoma AT danielmolin plasmaproteomeprofilingofcardiotoxicityinpatientswithdiffuselargebcelllymphoma AT martinhoglund plasmaproteomeprofilingofcardiotoxicityinpatientswithdiffuselargebcelllymphoma AT annaeriksson plasmaproteomeprofilingofcardiotoxicityinpatientswithdiffuselargebcelllymphoma AT gunillaenblad plasmaproteomeprofilingofcardiotoxicityinpatientswithdiffuselargebcelllymphoma |
_version_ |
1724281370816020480 |